# A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

> **NCT05474690** · PHASE3 · WITHDRAWN · sponsor: **Henan Cancer Hospital**

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
- **DRUG:** (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)

## Key facts

- **NCT ID:** NCT05474690
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-11
- **Primary completion:** 2023-03-28
- **Final completion:** 2024-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment guide. The treatment plan ECHP-THP in this study is not the optimal treatment plan, therefore this study was terminated.
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05474690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05474690, "A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05474690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*